The impact of ESG investing is too significant to ignore and with the battle for funds at its peak, the biotech industry needs to be at the forefront of the agenda. With impending mandates, the pressure is firmly on businesses to start thinking about their ESG proposition and how it may positively influence and affect the wider industry.
How can global business leaders deliver on ambitions of growth and reinvention?
An interview with Alistair Kirk, transformation programme expert and member of the UK’s Vaccine Taskforce.
Digital health startups and tech giants are using consumer technology to change the way patients access care, potentially disrupting the industry.
Gil Carrara, U.S. Managing Partner and Healthcare & Life Sciences Regional Leader, discusses new strategic opportunities stemming from the health and wellness sector this year.
The biotech industry has expanded rapidly in the past decade, with investment in biotechnology and pharmaceutical firms pouring in from venture capitalists.
